Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer

NCT00484432 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer Metastatic Recurrent

Interventions

DRUG: NGR-hTNF
DRUG: doxorubicin

Sponsor

AGC Biologics S.p.A.